Aggarwal R et al. PRESTO: A phase III, open-label study of androgen annihilation in patients with high-risk biochemically relapsed prostate cancer (AFT-19). ESMO 2022;Abstract LBA63.

Attard G et al. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: A meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet 2022;399(10323):447-60. Abstract

Bolla M et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002;360(9327):103-6. Abstract

Nabid A et al. Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized phase III trial. Eur Urol 2018;74(4):432-41. Abstract

Polkinghorn WR et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov 2013;3(11):1245-53. Abstract

Shore ND et al. EMBARK: A phase 3 randomized study of enzalutamide or placebo plus leuprolide acetate and enzalutamide monotherapy in high-risk biochemically recurrent prostate cancer. AUA 2023;Abstract LBA02-09.